Akèy › Kansè Ezofajyen › Massachusetts
Etid klinik pou Kansè Ezofajyen nan Massachusetts
25 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07578571A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
- Massachusetts General Hospital (Data Collection Only), Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06123338Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
- Massachusetts General Hospital, Boston
- UMass/Shields, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07217704Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898Resilience and Equity in Aging, Cancer, and Health (REACH)
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 65 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT04674267Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Boston
- Research Site, Burlington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07431281Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04188535Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
- Massachusetts General Hospital, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07070466A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07227168A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital - Dana Farber, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- ak 3 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 16, 2026 · NCT02584244SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.